> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# J&J Reports Favorable Data on Psoriasis Drug
- URL: https://www.fdaweb.com/j-j-reports-favorable-data-on-psoriasis-drug/
- Published: 2025-04-10T12:00:00.000Z
- Updated: 2026-09-14T14:57:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158983

Johnson & Johnson is reporting new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEAD, a Phase 3 registrational study in moderate-to-severe plaque psoriasis patients. The data show adolescents treated with once-daily icotrokinra achieved higher rates of clear or almost clear skin at Week 16 compared to patients receiving placebo with no new safety signals identified, it says.

“In the study, 84.1% of adolescent patients treated with once-daily icotrokinra achieved an Investigator’s Global Assessment (IGA) score of 0/1 (clear or almost clear skin) and 70.5% achieved a Psoriasis Area and Severity Index (PASI) 90 response, compared to 27.3% and 13.6% receiving placebo, respectively, at Week 16,” J&J says. “Response rates continued to improve through Week 24 where 86.4% of adolescents achieved IGA 0/1 (clear or almost clear skin) and 88.6% achieved PASI 90.”

Regarding safety, the company says icotrokinra demonstrated a favorable safety profile. At Week 16, 50% of adolescents treated with icotrokinra experienced greater than one adverse event, compared to 73% of adolescents receiving placebo, with no new safety signals identified.

Icotrokinra is described as a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.